- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02522962
Innovative Physiotherapy and Coordination of Care for People With MS: a RCT and a Qualitative Study (GroupCoreSIT)
Innovative Physiotherapy and Coordination of Care for People With Multiple Sclerosis: a Randomised Controlled Trial and a Qualitative Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This research project first aims to compare the effects of high-intensity individualized group-based core stability training (GroupCoreSIT) for people with MS with standard care in the primary health care focusing on balance, walking, ADL, quality of life and cost-effectiveness. Secondly, the project aims to investigate patients' experiences from participating in the intervention and in standard care, particularly addressing reflections regarding content, relevance and feasibility, changes in ADL, continuity of care, self-management. The third aim is to investigate how the PTs act and interact with the group while conducting the intervention, particularly how individualization is carried out, and the PTs' reflections from participating in the education and performance of the intervention. Finally, changes in patients' pathways and coordination represent another main objective of this project.
The RCT: hypothesis, study outcomes and measures:
High-intensity individualised group-based core stability training performed at the municipal PTs' facilities, complemented by home exercises, will improve balance, walking, ADL, quality of life and cost-effectiveness. This is reflected in the primary and secondary outcomes.
RCT will be conducted in collaboration with the outpatient clinic for people with MS at the Nordland Hospital Trust, Bodø, together with six municipalities in Nordland County. The municipalities are included: Bodø, Rana, Meløy, Rødøy, Vågan and Fauske. The out-patient clinic agreed to recruit the participants by sending a written invitation to people with MS in the selected municipalities, fulfilling the inclusion criteria. Six PTs with expertise in neurological physiotherapy agreed to conduct the intervention. These PTs will attend a four days practical and theoretical training on the intervention, with 1-2 follow up videoconferences during the study.
A prospective RCT will be conducted, in which 72 persons with MS will participate, undergo a 6-week intervention, and be followed up for 6 months. Participants will be randomly assigned to two arms in a 1:1 ratio. Participants in the intervention arm A will be offered individualised group-based core stability training termed GroupCoreSIT at the PTs facilities, complemented with home exercises. Participants in the control arm B will be offered standard care. Significant improvements in outcomes are expected for the intervention arm compared to standard care. Randomisation will be stratified by European Disability Score Scale (EDSS) to minimize selection bias and preserve homogeneity between arms. Randomisation and data collation will be performed using Remote Data Entry (WebCRF), an Internet-based solution developed by the Norwegian University of Science and Technology (NTNU). The researchers aim to recruit all subjects within 5 months.
After enrolment, the PTs responsible for performing the intervention, will conduct an individual assessment of the participants in arm A as a basis for individualisation in the group based intervention.
Each training group will consist of three participants. The training sessions will last for 60 minutes, performed three days per week, for six weeks, between 10 am and 5 pm. A total of 32 exercises with up to 5 levels of difficulty are described and illustrated by photos, will be available in an "exercise bank". 10-12 repetitions for each exercise with good quality of movement will be performed. Every session will end with active stretching/active relaxation and instructions for home exercises. The participants will perform 30-minute of exercises, optional to divide into smaller intervals, at home two days per week when there are no organized group training.
Intervention arm A: the participants will perform the training program: GroupCoreSIT in the facilities of the municipal physiotherapist.
Control arm B: the participants in the control group will receive standard care, i.e. following their ordinary physiotherapy services and/or routines/activities.
Procedures and tests The trial will be restricted to patients who have volunteered and provided written informed consent in accordance with the Declaration of Helsinki and the Ethics Committee procedures.
At enrolment, a neurologist will do the EDSS screening, medical history, type of MS and medications. An appropriately trained PT, also blinded to the arm membership, will perform a standardized assessment for all the participants using relevant tests and provide the activity monitor. The following baseline information will be collected and then inserted electronically in the WebCRF system used also to randomize the patients:
- Medical history, type of MS, EDSS, age, gender, weight, height, medications, physiotherapy during the previous 6 months.
- Two primary outcomes measuring balance in sitting, standing and walking.
- Nine secondary outcomes measuring balance, waling, activities of daily living (ADL), quality of life and physical activity At 1 week, 3 months and 6 months post intervention all the participants will undergo the same standardized assessment performed at baseline.
Exercise, activity and disease monitoring On a weekly basis all the participants will record: changes in medication, general wellbeing (qualitative self-score), exacerbations, and physical activities using a diary. The ActiGraph monitor will be used 1 week prior to intervention, 1 week post intervention and following the 3 and 6 months testing, demonstrated and delivered to the subjects by the test PT. In addition, participants in arm A will record: degree of exhaustion following group sessions (Borg scale) and home exercise completion (in the training diary).
An intention-to-treat analysis will be performed on all randomised subjects and will serve as the primary analysis for all outcomes in this study. The data analysis will be carried out using SPSS. Possible differences between the groups at baseline will be calculated by using independent sample t-test for continuous variables and chi-square for categorical variables. Primary outcomes, changes in balance and walking between the groups will be calculated by using independent sample t-test.
A cost-utility analysis will be conducted using healthcare system costs and quality adjusted life years (QALYs). QALYs will be calculated based on the answers of the Health Questionnaire (EQ-5D-3L) used to measure changes in patients' quality of life. The incremental cost-effectiveness ratio (ICER) will be computed as differential costs between intervention arm and standard arm over the study period, and differential QALYs. Healthcare utilisation (including hospitalisations, emergency department admissions, outpatients visits, examinations, primary care visits, rehabilitation) and related costs will be collected through the hospitals' electronic patient journal (DIPS), from the Norwegian Patient Registry and The Norwegian Health Economics Administration's (HELFO) system. This secondary outcome will provide relevant knowledge regarding new effective method in organising healthcare services. This can be used as a basis for decision making regarding large-scale implementation of rehabilitation.
Patients' experiences:
The patients' experiences with the intervention will be examined through qualitative research interviews. The interviews will be conducted on a sample of 8-10 participants from the intervention and the control arm twice; at the end of intervention and 6 months post intervention. In accordance with qualitative methods, the researchers will select the sample strategically to promote breadth and variety of data production. Variation in training groups, EDSS, age, gender and time since diagnosis are considered to be important. The interviews will take place in participants' homes or another convenient place in their municipality. The interview topics include: the first assessment/consultation, the group situation, content of training, intensity/quantity, pros and cons, home-exercises and ADL. The same number of subjects from the control group will be interviewed regarding their experiences with standard care, investigating the same topics. In order to provide insight into the users' experiences beyond the intervention period the scope for the second interviews is: retrospective reflections regarding wellbeing and coping with ADL in the period before, during and after the intervention, self-management, and continuity of care, pros and cons regarding the intervention and standard care. A theme-based interview guide will be used as well as audio recordings of the interviews. The material will be transcribed and analyzed using Systematic Text Condensation applying phenomenology of the body, enactive theory complemented by neurosciences as a theoretical framework.
Physiotherapists' performance of intervention and experiences:
What the PTs emphasize in their individual assessment prior to the first group session will be investigated through observation and videotaping of the assessment of one patient in each training group (12 observations). These observations will be complemented by qualitative research interview with the actual PT (12 interviews) to illuminate the PTs' reflections regarding the assessment, planning of the group sessions, choices of exercises and goals for the individual. To investigate how the PTs' tailor the intervention in situ, how they act and interact with the participants, one session in each group will be observed and videotaped (12 observations). To illuminate the PTs' reflections regarding education in the intervention, experiences from conducting it, particularly focusing on considerations regarding goal attainment, individualization in a group setting and home exercises, the PTs will be interviewed at the end of each training group period (12 interviews). An observation guide, a hand held video-camera and a theme-based interview guide will be used as well as audio recordings of the interviews. The material will be transcribed and analysed using Systematic Text Condensation applying phenomenology of the body, enactive theory complemented by neurosciences and practice knowledge as a theoretical framework.
Changes in patient's pathway and coordination of care:
In 2007 The Northern Norway Regional Health Authority (Helse Nord RHF) reported 650 persons with MS, the selected outpatient clinic has 300 persons enrolled, and prevalence and incidence in Nordland County have recently increased to a high risk area for MS. Courses for newly diagnosed persons have priority in the specialist care and current offer of complex rehabilitation, included high intensity physiotherapy is provided by the rehabilitation unit at UNN, The Rehabilitation Centre, the Kurbad of North Norway, Valnesfjord Rehabilitation Centre, supplemented by The National Hakadal MS centre. These institutions are currently characterised by long waiting lists. A system for early admission to neurological physiotherapy, and particularly to high intensity programs in the primary health care, is not established within the coordination of care for people with MS. Referral to municipality physiotherapy is not systematic, waiting lists in the primary health care are long, and services are often general and not specifically addressing the needs for people with MS.
To explore coordination of care between the outpatient clinics for people with MS and the municipalities regarding high intensity physiotherapy, qualitative interviews will be conducted with selected health personnel (MS-nurses, neurologists, PTs, a total of 8-10 subjects) at the hospitals' outpatient clinics and in municipalities (general practitioners, PTs, a total of 8-10 subjects), before the intervention (for the standard care) and after the RCT (for the new organizational model). The interviews will focus on structures for collaboration and content of service.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bodø, Norway
- Physiotherapy department, Nordlandssykehuset HF
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of MS (McDonald's criteria)
- EDSS 1-6.5 (minimal symptoms - able to walk 20 minimum meter with two crutches)
- Minimum 14 days post exacerbation
- Age >18 years
- Capable to provide signed written informed consent
Exclusion Criteria:
- Pregnancy at enrolment
- Acute orthopedic conditions affecting balance and walking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: GroupCoreSIT
Before the group training starts, the physiotherapist in charge of the group does a clinical assessment of each participant in order to individualise the training.
Each training group will consist of three participants.
The training sessions will last for 60 minutes, performed three days per week, for six weeks, between 10 am and 5 pm.
|
Each group session lasts for 60 minutes.
The physiotherapist will chose from an "exercises bank" of 32 exercises, each having up 5 levels of difficulty that are described and illustrated by photos.
All exercises demand core activation, emphasise normal movement and emphasise somatosensory integration, feed forward and feed back strategies essential for balance.10-12
repetitions for each exercise with good quality of movement will be performed.
Every session will start with exploring standing balance and end with active stretching/active relaxation, re-exploring balance and instructions for home exercises.
The participants will perform 30-minute of exercises, optional to divide into smaller intervals, at home two days per week when there are no organized group training.
Other Names:
|
|
Active Comparator: Standard care
The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities.
The content of standard care may vary, and will be recorded for all the participants.
|
The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities.
The content of standard care may vary, and will be recorded for all the participants.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Trunk Impairment Scale modified Norwegian Version
Time Frame: Baseline
|
The outcome measures sitting balance
|
Baseline
|
|
Measure change in the outcome: Trunk Impairment Scale modified Norwegian Version
Time Frame: 1 week post intervention
|
The outcome measures sitting balance
|
1 week post intervention
|
|
Measure change in the outcome: Trunk Impairment Scale modified Norwegian Version
Time Frame: 3 months post intervention
|
The outcome measures sitting balance
|
3 months post intervention
|
|
Measure a change in the outcome: Trunk Impairment Scale modified Norwegian Version
Time Frame: 6 months post intervention
|
The outcome measures sitting balance
|
6 months post intervention
|
|
Mini-Balance Evaluation Systems Test
Time Frame: baseline
|
The outcome measures standing and walking balance
|
baseline
|
|
Measure a change in the outcome: Mini-Balance Evaluation Systems Test
Time Frame: 1 week post intervention
|
The outcome measures standing and walking balance
|
1 week post intervention
|
|
Measure a change in the outcome:Mini-Balance Evaluation Systems Test
Time Frame: 3 months post intervention
|
The outcome measures standing and walking balance
|
3 months post intervention
|
|
Measure a change in the outcome: Mini-Balance Evaluation Systems Test
Time Frame: 6 months post intervention
|
The outcome measures standing and walking balance
|
6 months post intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
10-Meter Walk Test
Time Frame: Baseline
|
The outcome measures the speed of 10 meter walking
|
Baseline
|
|
Measure a change in the outcome: 10 Meter Walk Test
Time Frame: 1 week post intervention
|
The outcome measures the speed of 10 meter walking
|
1 week post intervention
|
|
Measure a change in the outcome:10 Meter Walk Test
Time Frame: 3 months post intervention
|
The outcome measures the speed of 10 meter walking
|
3 months post intervention
|
|
Measure a change in the outcome: 10 Meter Walk Test
Time Frame: 6 months post intervention
|
The outcome measures the speed of 10 meter walking
|
6 months post intervention
|
|
2-Minutes Walk Test
Time Frame: Baseline
|
The outcome measures the distance walked in 2 minutes
|
Baseline
|
|
Measure a change in the outcome: 2-Minutes Walk Test
Time Frame: 1 week post intervention
|
The outcome measures the distance walked in 2 minutes
|
1 week post intervention
|
|
Measure a change in the outcome:2-MinutesWalk Test
Time Frame: 3 months post intervention
|
The outcome measures the distance walked in 2 minutes
|
3 months post intervention
|
|
Measure a change in the outcome:2-Minutes Walk Test
Time Frame: 6 months post intervention
|
The outcome measures the distance walked in 2 minutes
|
6 months post intervention
|
|
Rivermead Visual Gait Assessment
Time Frame: Baseline
|
The outcome measures quality of movement in walking
|
Baseline
|
|
Measure a change in the outcome:Rivermead Visual Gait Assessment
Time Frame: 1 week post intervention
|
The outcome measures quality of movement in walking
|
1 week post intervention
|
|
Measure a change in the outcome:Rivermead Visual Gait Assessment
Time Frame: 3 months post intervention
|
The outcome measures quality of movement in walking
|
3 months post intervention
|
|
Measure a change in the outcome:Rivermead Visual Gait Assessment
Time Frame: 6 months post intervention
|
The outcome measures quality of movement in walking
|
6 months post intervention
|
|
MS Walking Scale-12
Time Frame: Baseline
|
a self-report form with 12 questions where limitations in various aspects of walking in the past two weeks are detected.
|
Baseline
|
|
Measure a change in the outcome:MS Walking Scale-12
Time Frame: 1 week post intervention
|
a self-report form with 12 questions where limitations in various aspects of walking in the past two weeks are detected.
|
1 week post intervention
|
|
Measure a change in the outcome:MS Walking Scale-12
Time Frame: 3 months post intervention
|
a self-report form with 12 questions where limitations in various aspects of walking in the past two weeks are detected.
|
3 months post intervention
|
|
Measure a change in the outcome: MS Walking Scale-12
Time Frame: 6 months post intervention
|
a self-report form with 12 questions where limitations in various aspects of walking in the past two weeks are detected.
|
6 months post intervention
|
|
Multiple Sclerosis Impact Scale-29
Time Frame: Baseline
|
A self-report form with 29 items which records limitations in various aspects of ADL
|
Baseline
|
|
Measure a change in the outcome:Multiple Sclerosis Impact Scale-29
Time Frame: 1 week post intervention
|
A self-report form with 29 items which records limitations in various aspects of ADL
|
1 week post intervention
|
|
Measure a change in the outcome:Multiple Sclerosis Impact Scale-29
Time Frame: 3 months post intervention
|
A self-report form with 29 items which records limitations in various aspects of ADL
|
3 months post intervention
|
|
Measure a change in the outcome:Multiple Sclerosis Impact Scale-29
Time Frame: 6 months post intervention
|
A self-report form with 29 items which records limitations in various aspects of ADL
|
6 months post intervention
|
|
The Patient Global Impression of Change
Time Frame: 1 week post intervention
|
a self-report form that measures the subject's perceptions of change
|
1 week post intervention
|
|
Measure a change in the outcome: Patient Global Impression of Change
Time Frame: 3 months post intervention
|
a self-report form that measures the subject's perceptions of change
|
3 months post intervention
|
|
Measure a change in the outcome: Patient Global Impression of Change
Time Frame: 6 months post intervention
|
a self-report form that measures the subject's perceptions of change
|
6 months post intervention
|
|
ActiGraph activity monitor.
Time Frame: baseline
|
The outcome measures physical activity
|
baseline
|
|
Measure a change in the outcome:ActiGraph activity monitor.
Time Frame: 1 week post intervention
|
The outcome measures physical activity
|
1 week post intervention
|
|
Measure a change in the outcome:ActiGraph activity monitor
Time Frame: 3 months post intervention
|
The outcome measures physical activity
|
3 months post intervention
|
|
Measure a change in the outcome:ActiGraph activity monitor
Time Frame: 6 months post intervention
|
The outcome measures physical activity
|
6 months post intervention
|
|
Multiple Sclerosis Quality of Life-54 (MSQOL-54)
Time Frame: Baseline
|
The outcome measures the participants' health related quality of life.
|
Baseline
|
|
Measure a change in the outcome:Multiple Sclerosis Quality of Life-54 (MSQOL-54)
Time Frame: 1 week post intervention
|
The outcome measures the participants' health related quality of life.
|
1 week post intervention
|
|
Measure a change in the outcome:Multiple Sclerosis Quality of Life-54 (MSQOL-54)
Time Frame: 3 months post intervention
|
The outcome measures the participants' health related quality of life.
|
3 months post intervention
|
|
Measure a change in the outcome:Multiple Sclerosis Quality of Life-54 (MSQOL-54)
Time Frame: 6 months post intervention
|
The outcome measures the participants' health related quality of life.
|
6 months post intervention
|
|
Health Questionnaire (EQ-5D-3L)
Time Frame: Baseline
|
The outcome measures the participants' health quality of life.
|
Baseline
|
|
Measure a change in the outcome:Health Questionnaire (EQ-5D-3L)
Time Frame: 1 week post intervention
|
The outcome measures the participants' quality of life.
|
1 week post intervention
|
|
Measure a change in the outcome:Health Questionnaire (EQ-5D-3L)
Time Frame: 3 months post intervention
|
The outcome measures the participants' quality of life.
|
3 months post intervention
|
|
Measure a change in the outcome:Health Questionnaire (EQ-5D-3L)
Time Frame: 6 months post intervention
|
The outcome measures the participants' quality of life.
|
6 months post intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Britt Normann, PhD, Nordlandssykehuset HF
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015/1715 REK
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States